Kanova

Kanova is a private Chinese biopharmaceutical company focused on therapeutic antibodies and combination therapies for oncology and autoimmune diseases. The company was founded in 2015 and is headquartered in Suzhou, with additional operations in Beijing and reported presence in Rockville, Maryland. Its disclosed pipeline includes XKH001, an anti-Interleukin-25 monoclonal antibody that has completed a Phase Ib multiple-ascending-dose study in healthy subjects, and XKH002, which is in Phase 1 testing for advanced or metastatic solid tumors. Third-party company databases describe Kanova as developing first-in-class or differentiated antibody programs for immunology and immuno-oncology. The company appears to be venture-backed, private, and active, with fundraising through at least a Series B1 round in July 2023.